Adding S-1 to standard chemo for advanced pancreatic cancer
Part of Cancer clinical trials.
This trial tests whether adding a third drug (S-1, a chemotherapy pill) to the standard two-drug IV chemo (albumin-bound paclitaxel and gemcitabine) can help people with advanced pancreatic cancer live longer. It's for those who haven't had treatment yet for their advanced cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer).
- You have not received any chemotherapy or other cancer treatment for your advanced or metastatic pancreatic cancer yet.
- If you had chemotherapy after surgery (adjuvant treatment), it must have been at least 6 months ago before the cancer came back.
- You are able to take pills by mouth.
- You are 18 years or older and in generally fair health (able to do light activities like walking or self-care).
- You have at least one tumor that can be measured on a CT scan or MRI.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new targeted drug called sotorasib combined with standard chemotherapy for people with advanced pancreatic cancer that has a specific KRAS G12C mutation. The goal is to see if the combination works better than chemotherapy alone.
This trial studies a chemotherapy combination (albumin-bound paclitaxel and gemcitabine) as first treatment for pancreatic cancer that cannot be removed by surgery. It aims to improve outcomes by testing how well this treatment works in people with locally advanced or metastatic disease.
This trial tests a combination chemotherapy plan—paclitaxel (albumin-bound), oxaliplatin, and S-1 given before surgery—to try to shrink stomach cancer and improve the chance of successful tumor removal. It is for people whose cancer is locally advanced or has spread, but might still be resectable (removable) in certain cases.
This trial tests whether taking an oral chemotherapy pill called S-1 after standard treatment can help prevent pancreatic cancer from coming back in people whose cancer had high-risk features. If you qualify, you would take S-1 for a period of time instead of just being watched.
This trial tests a new drug combo (cadonilimab plus either S-1 or capecitabine) for people with advanced pancreatic cancer that has not spread to other organs and who have already tried one standard treatment. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a new drug called IBI343 combined with standard chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.